Galsulfase

Summary

Galsulfase (CHEMBL1201822) is an approved enzyme (ATC A16AB08); indicated across 2 conditions including mucopolysaccharidosis type 6.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Enzyme
• ATC class: A16AB08
• Indications: 2 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201822
Name	Galsulfase
Type	Enzyme
Max phase	4
ATC	A16AB08

Also known as: Argyplase, Arylsulfatase b galsulfase, Aryplase, Galsulfasa, Galsulfase, Naglazyme, Neglazyme, GALSULFASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
mucopolysaccharidosis type 6	4	MONDO:0009661	MONDO:0009661
mucopolysaccharidosis	4	MONDO:0019249	MONDO:0019249

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	2
PHASE4	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00299000	PHASE4	COMPLETED	A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI
NCT00067470	PHASE3	COMPLETED	Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI
NCT00104234	PHASE3	COMPLETED	Study of rhASB in Patients With Mucopolysaccharidosis VI
NCT00048711	PHASE2	COMPLETED	Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI
NCT00048620	PHASE1	COMPLETED	Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).